Trials / Recruiting
RecruitingNCT06709651
Microbiome Immunotherapy Neoadjuvant Assessment
Prospective Evaluation of the Breast Microbiome and Tumor Microenvironment-related Biomarkers of Response to Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- University College Cork · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Predictive biomarkers of response to combination chemotherapy and immune-checkpoint inhibitors are urgently needed to help tailor treatment recommendations for patients with early-stage TNBC. Tumour-associated microbiota in primary breast tumours represent promising and novel candidate biomarkers modulators of the efficacy of therapies for patients with TNBC. It has been shown that microbes colonizing breast tumours can modulate the efficacy of commonly used drugs and that the microbiome of breast tissue biopsies could represent a new biomarker. Data on the microbiome of patients with cancer indicate the potential for a new class of bacteria-based oncological biomarkers, for exploitation in precision oncology.
Conditions
Timeline
- Start date
- 2024-10-02
- Primary completion
- 2026-11-01
- Completion
- 2027-11-01
- First posted
- 2024-11-29
- Last updated
- 2026-03-04
Locations
1 site across 1 country: Ireland
Source: ClinicalTrials.gov record NCT06709651. Inclusion in this directory is not an endorsement.